Contineum Therapeutics (CTNM) investor relations material

Portfolio and clinical programs

• PIPE-791, an internally derived LPA1 antagonist, is in a phase II IPF study; PIPE-307, a first-in-class M1 receptor inhibitor, is partnered with Johnson & Johnson.

• MOONLIGHT-1 tested PIPE-307 in MDD with a two-week regimen and MADRS change at day 5; the primary endpoint was missed, while prespecified exploratory endpoints are under evaluation with Johnson & Johnson.

LPA1 class and differentiation

• Admilparant’s phase II included ~1,200 patients over 52 weeks; 60 mg BID achieved statistical significance and clinical efficacy, while 120 mg BID missed statistical significance but reduced FVC decline versus placebo.

• Further admilparant data, including secondary endpoints and liver safety details, are anticipated at ATS in May; the speaker viewed the phase III advancement as clinical validation of LPA1.

• Human PET and multiple-ascending-dose studies showed >90% receptor occupancy at 1 mg, 3 mg and 10 mg with once-daily PIPE-791; the speaker cited sustained coverage and a slow-on/slow-off profile as differentiators.

• No adverse signals, including blood pressure changes, were reported in completed PIPE-791 studies; the speaker sees LPA1 as a potential foundation for combination therapy in IPF.

PROPEL-IPF and development plans

• PROPEL-IPF is enrolling ~324 patients, with 108 per arm, globally across a 26-week study; primary endpoint is absolute change in FVC versus placebo, with completion targeted for mid-2028.

• More than 100 sites across nearly 20 territories were established; full-enrollment updates are likely, and trial sites and territories can be tracked on ClinicalTrials.gov.

• The study includes exploratory pain and cough endpoints, and will monitor blood pressure, liver function tests and bilirubin.

• Longer-term development beyond IPF may include progressive pulmonary fibrosis; the speaker also sees potential to address pain associated with fibrotic disease.